Catalogo Articoli (Spogli Riviste)

OPAC HELP

Titolo:
Doxorubicin plus ifosfamide as salvage treatment for patients with advanced breast cancer refractory to epirubicin plus cyclophosphamide
Autore:
Polyzos, A; Kosmas, C; Tsavaris, N; Markopoulos, C; Kalahanis, N; Papadopoulos, O; Arnaouti, T; Sfikakis, PP;
Indirizzi:
Univ Athens, Sch Med, Dept Propaedeut Med 1, Laikon Hosp, GR-11527 Athens,Greece Univ Athens Athens Greece GR-11527 , Laikon Hosp, GR-11527 Athens,Greece Helena Venizelou Hosp, Med Oncol Unit, Athens, Greece Helena Venizelou Hosp Athens Greece osp, Med Oncol Unit, Athens, Greece Univ Athens, Sch Med, Dept Pathophysiol, Laikon Hosp, GR-11527 Athens, Greece Univ Athens Athens Greece GR-11527 Laikon Hosp, GR-11527 Athens, Greece Univ Athens, Sch Med, Dept Surg, Laikon Hosp, GR-11527 Athens, Greece UnivAthens Athens Greece GR-11527 Laikon Hosp, GR-11527 Athens, Greece
Titolo Testata:
CLINICAL DRUG INVESTIGATION
fascicolo: 5, volume: 19, anno: 2000,
pagine: 349 - 355
SICI:
1173-2563(200005)19:5<349:DPIAST>2.0.ZU;2-0
Fonte:
ISI
Lingua:
ENG
Soggetto:
PHASE-II TRIAL; HIGH-DOSE IFOSFAMIDE; PACLITAXEL; THERAPY; DOCETAXEL; INFUSION; TOXICITY; MESNA; DRUG;
Tipo documento:
Article
Natura:
Periodico
Settore Disciplinare:
Clinical Medicine
Life Sciences
Citazioni:
36
Recensione:
Indirizzi per estratti:
Indirizzo: Polyzos, A Univ Athens, Sch Med, Dept Propaedeut Med 1, Laikon Hosp, GR-11527 Athens,Greece Univ Athens Athens Greece GR-11527 sp, GR-11527 Athens,Greece
Citazione:
A. Polyzos et al., "Doxorubicin plus ifosfamide as salvage treatment for patients with advanced breast cancer refractory to epirubicin plus cyclophosphamide", CLIN DRUG I, 19(5), 2000, pp. 349-355

Abstract

Objective: To investigate the response and toxicity of a salvage regimen in patients with advanced breast cancer whose tumours became resistant to fluorouracil-epirubicin-cyclophosphamide (FEC). By substituting doxorubicin for epirubicin and ifosfamide for cyclophosphamide, we aimed to evaluate thepossible lack of cross-resistance between the two anthracyclines and the two alkylating agents. Patients and Participants: The study included 37 evaluable patients with histologically or cytologically proven breast cancer and evidence of progressive metastatic disease whose disease had progressed under FEC chemotherapy(15 patients) or had recurred within 6 months after FEC chemotherapy (22 patients). Interventions: A regimen of intravenous doxorubicin 50 mg/m(2) on day 1 plus intravenous ifosfamide 5 g/m(2) delivered over 2 days with mesna plus intravenous fluorouracil 600 mg/m(2) on day 1 was administered every 4 weeks. Nonresponding patients after two courses of treatment received intravenouspaclitaxel 175 mg/m(2) over 3 hours. Results: Objective response was achieved by eight patients, with one complete and seven partial responses (21%; 95% confidence interval 10 to 38%). Median response duration was 3 months (range 2 to 7 months), time to progression was 5 months (3 to s months) and survival was 8 months (4 to 20 months). Myelotoxicity was significant, with five episodes of neutropenic fever, and 10 patients developed congestive heart failure. Cardiac toxicity developed in patients who received a median cumulative dose of >200 mg/m(2) of epirubicin plus 400 mg/m(2) of doxorubicin. Conclusion: Administration of doxorubicin plus ifosfamide in patients withtumour recurrence after FEC chemotherapy represents a moderately effectiveregimen, suggesting that the two anthracyclines and the two alkylating agents sequential administration of anthracyclines precludes use of this regimen in patients with impaired cardiac function and in those who have received a cumulative dose of anthracyclines >600 mg/m(2).

ASDD Area Sistemi Dipartimentali e Documentali, Università di Bologna, Catalogo delle riviste ed altri periodici
Documento generato il 24/09/20 alle ore 02:11:27